2024-08-23
Independent Front Page 23rd of August 2024
The Independent reports that regulators have approved the Alzheimer’s drug lecanemab, but it is deemed too costly for NHS patients.
2024-08-23
Guardian Front Page 23rd of August 2024
The return of GCSE results to pre-pandemic levels has sparked concerns over the widening ‘attainment gap,’ with significant regional variations in exam grades across the UK, according to education officials.
2024-08-23
Daily Mail Front Page 23rd of August 2024
Regulators have licensed a new therapy proven to slow Alzheimer’s disease but have restricted its availability on the NHS due to cost concerns, meaning patients must go private for treatment.
2024-08-23
Daily Mirror Front Page 23rd of August 2024
TV presenter Jermaine Jenas has been sacked by the BBC over claims of inappropriate behaviour involving a female member of staff, leading to his removal from “Match of the Day” and “The One Show.”
2024-08-23
Daily Star Front Page 23rd of August 2024
Storm Lilian is set to hit Britain with 75mph winds and torrential rain, but a heatwave is expected to follow by the end of August.
2024-08-23
Daily Express Front Page 23rd of August 2024
A drug for dementia patients, while approved for private use, has been rejected by the NHS, raising concerns over its accessibility only to the wealthy.
2024-08-23
Daily Telegraph Front Page 23rd of August 2024
Patients in the UK will be denied access to a promising Alzheimer’s treatment on the NHS as NICE has ruled out its funding due to high costs and minimal estimated benefit.
2024-08-23
i Front Page 23rd of August 2024
Trade union leaders in the UK are divided over the best approach to securing favourable pay deals from the Chancellor, with some advocating for a more aggressive stance while others prefer a quieter, more diplomatic strategy.
2024-08-23
Financial Times Front Page 23rd of August 2024
AstraZeneca has warned it could move its vaccine plant to the US due to concerns over the UK government potentially cutting aid that supports drug manufacturing and research, with Philadelphia offering incentives to attract the company.